Welcome to JOURNAL OF SICHUAN UNIVERSITY (MEDICAL SCIENCES) July 19, 2025
ZENG Xi, LI Jing, KANG Le-ni, et al. Effectiveness of Different Testing Strategies Applied for Cervical Cancer Screening in Shuangliu District, Chengdu City[J]. Journal of Sichuan University (Medical Sciences), 2022, 53(5): 896-903. DOI: 10.12182/20220960502
Citation: ZENG Xi, LI Jing, KANG Le-ni, et al. Effectiveness of Different Testing Strategies Applied for Cervical Cancer Screening in Shuangliu District, Chengdu City[J]. Journal of Sichuan University (Medical Sciences), 2022, 53(5): 896-903. DOI: 10.12182/20220960502

Effectiveness of Different Testing Strategies Applied for Cervical Cancer Screening in Shuangliu District, Chengdu City

More Information
  • Corresponding author:

    CHEN Min-yan, E-mail: nnccmmyy@163.com

  • Received Date: December 05, 2021
  • Revised Date: August 14, 2022
  • Available Online: September 25, 2022
  • Published Date: September 19, 2022
  •   Objective  To evaluate the clinical value of different combination strategies of high-risk HPV (hr-HPV) testing and Thinprep cytology test (TCT), a cervical cytology test, for cervical cancer screening, especially for high or higher-grade squamous intraepithelial lesion (HSIL+) in Shuangliu District, Chengdu City.
      Methods  The study is a population-based randomized clinical trial. Women aged 35 to 65 years meeting the inclusion criteria were enrolled for the study. At the baseline screening conducted in the first year, the participants were randomly assigned to either cytology test or hr-HPV testing at a ratio of 1∶2. If the paticipants had positive results for the baseline hr-HPV test, they would then undergo either cytology test or colposcopy by random assignment. After 24 months, all participants were called back, and combined screening of cytology test and hr-HPV test were performed. Women who had negative results at baseline screening and who entered and completed the third-year follow-up were selected as the subjects of the study. Based on the aforementioned testing findings, the related data were extracted and four different screening protocols were simulated: 1) combined TCT and hr-HPV screening, with referral for colposcopy when there was positive results for either one of the two; 2) combined TCT and hr-HPV screening, with referral for colposcopy when both tests had positive results at the same time; 3) TCT was done for preliminary screening and those who were found to be positive would then undergo hr-HPV test for triage purpose, with subsequent referral made for colposcopy if the hr-HPV results were positive; 4) hr-HPV was done for preliminary screening and those who were found to be positive would then undergo TCT, with subsequent referral made for colposcopy if TCT results were positive. With the detection of HSIL+ on histological examination as the endpoint event, the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and area under curve (AUC) of different combination screening models were calculated.
      Results  A total of 3102 women were screened, and 2967 women were included in the statistical analysis in this study. Among the 2967 women, 979 were randomized to cytology and 1988 to hr-HPV genotyping. For prescreening, the positive rate of the cytology group was 5.6% (55/979), with of HSIL+ positive rate being 0.2% (2/979), while the positive rate of the hr-HPV group was 7.5% (149/1988), with HSIL+ positive rate being 0.9% (18/1988). After 24 months, 2456 women were called back and were given cervical cytology test and hr-HPV test at the same time. Among them, the positive rate of the cytology group was 3.2% (78/2456), while the positive rate of hr-HPV group was 8.7% (215/2456). The overall positive rate of HSIL+ was 0.69%(17/2456). Women with a negative baseline hr-HPV had a lower incidence of HSIL+ lesions in the long term. The strategy of cervical cytology screening combined with hr-HPV test for triage purpose is the best method, with a sensitivity of 88.9%, a specificity of 58.3%, a PPV of 44.4%, a NPV of 93.3%, and an AUC of 0.736, P=0.039 (95% CI: 0.555-0.917).
      Conclusion  This randomized clinical trial from Shuangliu District, Chengdu City shows that the sensitivity of hr-HPV testing is better than that of cytology test, and the prevalence of HSIL+ in women with negative baseline hr-HPV results is lower than that of women with negative baseline cytology results. The screening program of TCT for prescreening plus subsequent hr-HPV test for triage purpose shows better value for the detection of HSIL+.
  • [1]
    SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin,2021,71(3): 209–249. DOI: 10.3322/caac.21660
    [2]
    BHATLA N, SINGHAL S. Primary HPV screening for cervical cancer. Best Pract Res Clin Obstet Gynaecol,2020,65: 98–108. DOI: 10.1016/j.bpobgyn.2020.02.008
    [3]
    CHOI Y J, PARK J S. Clinical significance of human papillomavirus genotyping. J Gynecol Oncol, 2016, 27(2): e21[2021-11-20].https://doi.org/10.3802/jgo.2016.27.e21.
    [4]
    SPENCE A R, GOGGIN P, FRANCO E L. Process of care failures in invasive cervical cancer: Systematic review and meta-analysis. Prev Med,2007,45(2/3): 93–106. DOI: 10.1016/j.ypmed.2007.06.007
    [5]
    CHEN L, ZHANG Y, YOUNG R, et al. Effects of vaccine-related conspiracy theories on Chinese young adults’ perceptions of the HPV vaccine: An experimental study. Health Commun,2021,36(11): 1343–1353. DOI: 10.1080/10410236.2020.1751384
    [6]
    SAWAYA G F, SMITH-MCCUNE K, KUPPERMANN M. Cervical cancer screening: More choices in 2019. JAMA,2019,321(20): 2018–2019. DOI: 10.1001/jama.2019.4595
    [7]
    DERBIE A, MEKONNEN D, WOLDEAMANUEL Y, et al. HPV E6/E7 mRNA test for the detection of high grade cervical intraepithelial neoplasia (CIN2+): A systematic review. Infect Agent Cancer, 2020, 15: 9[2021-11-20]. https://doi.org/10.1186/s13027-019-0268-z.
    [8]
    XUE P, GAO L L, YIN J, et al. A direct comparison of four high-risk human papillomavirus tests versus the cobas test: Detecting CIN2+ in low-resource settings. J Med Virol,2019,91(7): 1342–1350. DOI: 10.1002/jmv.25451
    [9]
    LI Y, MA L, YANG C, et al. A study on service capacity of primary medical and health institutions for cervical cancer screening in urban and rural areas in China. Chin J Cancer Res,2019,31(5): 838–848. DOI: 10.21147/j.issn.1000-9604.2019.05.13
    [10]
    ZHANG S K, JIA M M, ZHAO D M, et al. Evaluation of p16/Ki-67 dual staining in the detection of cervical precancer and cancer in China. Cancer Epidemiol,2019,59: 123–128. DOI: 10.1016/j.canep.2018.12.013
    [11]
    PANKAJ S, NAZNEEN S, KUMARI S, et al. Comparison of conventional Pap smear and liquid-based cytology: A study of cervical cancer screening at a tertiary care center in Bihar. Indian J Cancer,2018,55(1): 80–83. DOI: 10.4103/ijc.IJC_352_17
    [12]
    WANG M Z, FENG R M, WANG S, et al. Clinical performance of human papillomavirus testing and visual inspection with acetic acid in primary, combination, and sequential cervical cancer screening in China. Sex Transm Dis,2019,46(8): 540–547. DOI: 10.1097/OLQ.0000000000001026
    [13]
    ZHENG B, AUSTIN R M, LIANG X, et al. PPV of an HSIL cervical cytology result in China's largest CAP-certified laboratory. J Am Soc Cytopathol,2015,4(2): 84–89. DOI: 10.1016/j.jasc.2014.10.005
    [14]
    CHAN K K, LIU S S, WEI N, et al. Primary HPV testing with cytology versus cytology alone in cervical screening--A prospective randomized controlled trial with two rounds of screening in a Chinese population. Int J Cancer,2020,147(4): 1152–1162. DOI: 10.1002/ijc.32861
    [15]
    宋波, 吴久玲, 宋莉, 等. 2012年我国农村妇女宫颈癌检查状况分析. 中国妇幼卫生杂志,2015,6(1): 1–4. DOI: 10.19757/j.cnki.issn1674-7763.2015.01.001
    [16]
    COLDMAN A J, VAN NIEKERK D, KRAJDEN M, et al. Disease detection at the 48-month exit round of the HPV FOCAL cervical cancer screening trial in women per-protocol eligible for routine screening. Int J Cancer,2020,146(7): 1810–1818. DOI: 10.1002/ijc.32524
    [17]
    WANG Z, WANG T, YANG J, et al. Diagnostic yield and performance of a large population-based cervical cancer screening program in high-risk rural China. J Cancer,2020,11(13): 4000–4006. DOI: 10.7150/jca.41472
    [18]
    OGILVIE G S, KRAJDEN M, VAN NIEKERK D, et al. HPV for cervical cancer screening (HPV FOCAL): Complete Round 1 results of a randomized trial comparing HPV-based primary screening to liquid-based cytology for cervical cancer. Int J Cancer,2017,140(2): 440–448. DOI: 10.1002/ijc.30454
    [19]
    LIN C Q, ZENG X, CUI J F, et al. Stability study of cervical specimens collected by swab and stored dry followed by human papillomavirus DNA detection using the cobas 4800 test. J Clin Microbiol,2017,55(2): 568–573. DOI: 10.1128/JCM.02025-16
    [20]
    OGILVIE G S, VAN NIEKERK D, KRAJDEN M, et al. Effect of screening with primary cervical HPV testing vs cytology testing on high-grade cervical intraepithelial neoplasia at 48 months: the HPV FOCAL randomized clinical trial. JAMA,2018,320(1): 43–52. DOI: 10.1001/jama.2018.7464
    [21]
    KOLIOPOULOS G, NYAGA V N, SANTESSO N, et al. Cytology versus HPV testing for cervical cancer screening in the general population. Cochrane Database Syst Rev,2017,8(8): CD008587. DOI: 10.1002/14651858.CD008587.pub2
    [22]
    TERMRUNGRUANGLERT W, KHEMAPECH N, TANTITAMIT T, et al. Cost effectiveness analysis of HPV primary screening and dual stain cytology triage compared with cervical cytology. J Gynecol Oncol, 2019, 30(2): e17[2021-11-20]. https://doi.org/10.3802/jgo.2019.30.e17.
    [23]
    ARBYN M, ANTTILA A, JORDAN J, et al. European guidelines for quality assurance in cervical cancer screening--Summary document. Ann Oncol,2010,21(3): 448–458. DOI: 10.1093/annonc/mdp471
    [24]
    ZHANG S, MCNAMARA M, BATUR P. Cervical cancer screening: What's new? Updates for the busy clinician. Am J Med,2018,131(6): 702.e701–702.e705.
    [25]
    HE L, HE J. Distribution of high-risk HPV types among women in Sichuan province, China: A cross-sectional study. BMC Infect Disv,2019,19(1): 390. DOI: 10.1186/s12879-018-3567-x
    [26]
    ANDERSEN B, NJOR S H, JENSEN A M S, et al. HrHPV testing vs liquid-based cytology in cervical cancer screening among women aged 50 and older: A prospective study. Int J Gynecol Cancer,2020,30(11): 1678–1683. DOI: 10.1136/ijgc-2020-001457
    [27]
    SUTEU O, BLAGA M L, NYGÅRD M, et al. Prevalence of positive screening test results and agreement between cytology and human papillomavirus testing in primary cervical cancer screening in North-Western Romania. Eur J Cancer Prev,2020,29(2): 141–148. DOI: 10.1097/CEJ.0000000000000522
    [28]
    CHEN X, XU H, XU W, et al. Prevalence and genotype distribution of human papillomavirus in 961, 029 screening tests in southeastern China (Zhejiang Province) between 2011 and 2015. Sci Rep,2017,7(1): 14813. DOI: 10.1038/s41598-016-0028-x
    [29]
    ALTHOFF K N, PAUL P, BURKE A E, et al. Correlates of cervicovaginal human papillomavirus detection in perimenopausal women. J Womens Health (Larchmt),2009,18(9): 1341–1346. DOI: 10.1089/jwh.2008.1223
    [30]
    MA L, WANG Y, GAO X, et al. Economic evaluation of cervical cancer screening strategies in urban China. Chin J Cancer Res,2019,31(6): 974–983. DOI: 10.21147/j.issn.1000-9604.2019.06.13

Catalog

    Recommendations
    Characteristics of aurora kinase a-mediated tumor microenvironment in colorectal cancer and mining of active compounds from chinese herbs
    LI Mengyao et al., JOURNAL OF SICHUAN UNIVERSITY (MEDICAL SCIENCES), 2025
    Advances in multi-omics analysis of cervical cancer
    WANG Jianhong et al., JOURNAL OF SICHUAN UNIVERSITY (MEDICAL SCIENCES), 2025
    Application of magnetic resonance imaging in the diagnosis and treatment of middle compartment defect
    LUO Shuyu et al., JOURNAL OF SICHUAN UNIVERSITY (MEDICAL SCIENCES), 2025
    Reproductive health-oriented development in assisted reproductive technologies
    HU Peiran et al., JOURNAL OF SICHUAN UNIVERSITY (MEDICAL SCIENCES), 2024
    Cytology versus molecular diagnosis of hpv for cervical cancer screening. comparison of the diagnostic properties of four tests in a rural community of cuenca ecuador
    Bernardo Vega Crespo et al., ESPOCH CONGRESSES: THE ECUADORIAN JOURNAL OF S.T.E.A.M., 2023
    Study on the mechanism of chinese medicine in treating cervical spondylosis
    Jiayi Liu et al., INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2024
    Barriers to cervical cancer screening in africa: a systematic review
    Mantula, Fennie et al., BMC PUBLIC HEALTH, 2024
    Racial and ethnic disparities in cervical cancer screening from three us healthcare settings
    Spencer, Jennifer C., AMERICAN JOURNAL OF PREVENTIVE MEDICINE, 2023
    Clinical utility of hpv typing and quantification combined with pax1/znf582 methylation detection in accurate cervical cancer screening
    CYTOJOURNAL, 2023
    Precision strike strategy for liver diseases trilogy with xiao-chai-hu decoction: a meta-analysis with machine learning
    PHYTOMEDICINE, 2025
    Powered by
    Article views (582) PDF downloads (33) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return